OraSure Technologies (NASDAQ:OSUR) Stock Rating Lowered by StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

OraSure Technologies Trading Up 1.0 %

Shares of OSUR opened at $3.93 on Thursday. OraSure Technologies has a 1 year low of $3.52 and a 1 year high of $8.04. The stock has a market cap of $293.14 million, a P/E ratio of 26.20 and a beta of 0.05. The stock’s 50-day moving average price is $3.81 and its two-hundred day moving average price is $4.05.

Hedge Funds Weigh In On OraSure Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OSUR. Tower Research Capital LLC TRC boosted its holdings in OraSure Technologies by 202.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 5,234 shares during the last quarter. Causeway Capital Management LLC bought a new position in shares of OraSure Technologies during the 4th quarter valued at about $36,000. Raymond James Financial Inc. bought a new position in shares of OraSure Technologies during the 4th quarter valued at about $37,000. Boothbay Fund Management LLC bought a new position in shares of OraSure Technologies during the 4th quarter valued at about $42,000. Finally, Atom Investors LP bought a new position in shares of OraSure Technologies during the 3rd quarter valued at about $49,000. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.